Abstract
Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2570-2574 |
| Number of pages | 5 |
| Journal | Blood |
| Volume | 133 |
| Issue number | 24 |
| DOIs | |
| State | Published - 2019 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Fingerprint
Dive into the research topics of 'Acalabrutinib for mantle cell lymphoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS